Transcranial Direct Current Stimulation as a Novel Therapeutic Approach in Amyotrophic Lateral Sclerosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01569958|
Recruitment Status : Unknown
Verified October 2012 by Alessandra Lugaresi, Università degli Studi 'G. d'Annunzio' Chieti e Pescara.
Recruitment status was: Recruiting
First Posted : April 3, 2012
Last Update Posted : October 10, 2012
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by progressive weakness and muscular atrophy due to the degeneration and loss of motor neurons, the nerve cells that, in the central nervous system (motor cortex, brainstem and spinal chord), control voluntary movement. Riluzole, the only drug approved for ALS treatment, modestly slow disease progression.
Transcranial direct current stimulation (tDCS) is a noninvasive technique of neuromodulation that is currently studied as a possible therapeutic tool for several neurological and psychiatric diseases and has been found safe and well tolerated. Based on experimental evidence in animals and human subjects, tDCS is expected to reduce motor cortex excitability and excitotoxicity, that is neuronal injury induced by excessive glutamatergic stimulation, one of postulated pathophysiological mechanisms in ALS.
This study will investigate if transcranial direct current stimulation of motor cortex is useful in delaying disease progression and is well tolerated in ALS patients.
|Condition or disease||Intervention/treatment||Phase|
|Amyotrophic Lateral Sclerosis||Other: transcranial direct current stimulation Other: Sham stimulation||Phase 2|
This is a double blind, randomized, placebo-controlled clinical trial.
Cathodic tDCS (1 mA for 20 minutes) will be sequentially applied over the motor cortex of both sides, for five consecutive days every month for twelve months. The control group will receive a sham stimulation that reproduce tactile sensation of real stimulation but has no effects on central nervous system. For stimulation, researchers will employ a CE-certified medical device acting as a micro-processor-controlled constant current source. All patients will take riluzole during the entire period of the study.
Fifty-four participants will be recruited from three Italian Centers and randomized to one of two arms of the study.
Disease progression and quality of life will be evaluated at baseline and every three months during the study.
At each visit adverse events will be reported and tolerability will be assessed through a specific questionnaire.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||54 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Transcranial Direct Current Stimulation as a Novel Therapeutic Approach in Amyotrophic Lateral Sclerosis|
|Study Start Date :||July 2012|
|Estimated Primary Completion Date :||April 2016|
|Estimated Study Completion Date :||April 2016|
|Active Comparator: tDCS||
Other: transcranial direct current stimulation
transcranial direct current stimulation applied to the motor cortex of both sides (1 mA, 20 minutes) for five consecutive days every month for 12 months
|Sham Comparator: sham||
Other: Sham stimulation
1 mA stimulation for 30 seconds every 900 seconds per session
- Decline of ALSFRS-R (ALS functional rating scale-revised) from baseline to 12 months [ Time Frame: 12 months ]
- Decline of muscle strength from baseline to 12 months [ Time Frame: 12 months ]A megascore will be obtained by summing scores of single muscles manually tested according to the Medical Research Council Scale
- Change of upper motor neuron signs from baseline to 12 months [ Time Frame: 12 months ]A score will be obtained based on presence/absence of listed upper motor neuron signs and grade of spasticity
- Decline of forced vital capacity (percent of predicted normal) from baseline to 12 months [ Time Frame: 12 months ]
- Change of quality of life from baseline to 12 months [ Time Frame: 12 months ]The ALSAQ-40 questionnaire will be employed
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01569958
|Centro Regionale Malattie Neuromuscolari, Ospedale Clinicizzato "SS. Annunziata"||Recruiting|
|Chieti, Italy, 66013|
|Contact: Margherita Capasso, MD, PhD 00390871358585 email@example.com|
|Principal Investigator: Alessandra Lugaresi, MD, PhD|
|Sub-Investigator: Margherita Capasso, MD,PhD|
|Azienda Policlinico Università Federico II||Not yet recruiting|
|Napoli, Italy, 80131|
|Principal Investigator: Lucio Santoro, MD|
|Policlinico Universitario Agostino Gemelli||Not yet recruiting|
|Rome, Italy, 00168|
|Principal Investigator: Vincenzo Di Lazzaro, MD|
|Principal Investigator:||Alessandra Lugaresi, MD, PhD||Università "G. d'Annunzio" di Chieti e Pescara, Dipartimento Neuroscienze ed Imaging, and ASL n. 2 Lanciano-Vasto-Chieti|